ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com




1. 5ÔÂ7ÈÕ£¬£¬£¬£¬£¬£¬CDE¹ÙÍøÏÔʾ£¬£¬£¬£¬£¬£¬ÌÚÊ¢²©Ò©µÄBRII-835 (VIR-2218) ×¢ÉäÒºÄâÄÉÈëÍ»ÆÆÐÔÖÎÁÆÆ·ÖÖ£¬£¬£¬£¬£¬£¬ÄâÓÃÓÚÖÎÁÆÂýÐÔÒÒÐ͸ÎÑײ¡¶¾£¨HBV£©Ñ¬È¾ºÍÂýÐÔÒÒÐ͸ÎÑײ¡¶¾£¨HBV£©/¶¡Ð͸ÎÑײ¡¶¾£¨HDV£©Ñ¬È¾¡£¡£¡£¡£¡£¡£
2. 5ÔÂ7ÈÕ£¬£¬£¬£¬£¬£¬¼â·å¼¯ÍÅÐû²¼Í¨¸æ£¬£¬£¬£¬£¬£¬È«×Ê×Ó¹«Ë¾Õã½¼â·åÒ©ÒµµÄËû·úǰÏßËØµÎÑÛÒºÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú׼ǩ·¢µÄ¡¶Ò©Æ·×¢²áÖ¤Êé¡·£¬£¬£¬£¬£¬£¬¸ÃÒ©ÓÃÓÚ½µµÍ¿ª½ÇÐÍÇà¹âÑۺ͸ßÑÛѹ֢»¼ÕßÉý¸ßµÄÑÛѹ¡£¡£¡£¡£¡£¡£
3. 5ÔÂ7ÈÕ£¬£¬£¬£¬£¬£¬ÉîÐÅÉúÎï´ø×´ðåÕîIN001 mRNAÒßÃçµÄÁÙ´²ÊÔÑéÉêÇë»ñµÃNMPAÊÜÀí¡£¡£¡£¡£¡£¡£¾ÝÉîÐÅÉúÎï½éÉÜ£¬£¬£¬£¬£¬£¬2023Äê9Ô£¬£¬£¬£¬£¬£¬ÕâÒ»mRNAÒßÃçºòÑ¡²úÆ·ÔÚÃÀ¹ú»ñÅúIND£¬£¬£¬£¬£¬£¬ÊǼÌModernaºÍ»ÔÈð/BioNTechÖ®ºóÈ«ÇòµÚÈý¿îÔÚͬÑùmRNA¼¼Êõõè¾¶»ñµÃÃÀ¹úFDAÁÙ´²ÊµÑéÔÊÐíµÄ´ø×´ðåÕîÒßÃç²úÆ·¡£¡£¡£¡£¡£¡£
1. 5ÔÂ8ÈÕ£¬£¬£¬£¬£¬£¬ÄϾ©Èð³õÒ½Ò©ÓÐÏÞ¹«Ë¾Ðû²¼Íê³ÉÉÏÒÚÔªPre-AÂÖÈÚ×Ê£¬£¬£¬£¬£¬£¬±¾ÂÖÈÚ×ÊÓÉÁúÅÍͶ×ÊÁìͶ£¬£¬£¬£¬£¬£¬µÂÁª×ÊÔ´ºÍ¶¦ÐÄ×ÊÔ´¸úͶ£¬£¬£¬£¬£¬£¬×ʽð½«ÓÃÓÚÍÆ½øÈð³õÒ½Ò©½¹µãÏîÄ¿µÄÁÙ´²É걨ºÍ¿ª·¢ÊÂÇé¡£¡£¡£¡£¡£¡£
2. 5ÔÂ7ÈÕ£¬£¬£¬£¬£¬£¬ÏÈΪ´ïÐû²¼£¬£¬£¬£¬£¬£¬ÒѾÓ뺫¹úÖÆÒ©¹«Ë¾HK inno.N Corporation¸æ¿¢ÁËÏàÖúÐÒ飬£¬£¬£¬£¬£¬ÔÊÐíºóÕßÔÚº«¹úÇøÓò¿ª·¢ºÍÉÌÒµ»¯ÒÁŵ¸ñ³ëÄ×¢ÉäÒº£¨Ecnoglutide£¬£¬£¬£¬£¬£¬XW003£©
1. 5ÔÂ3ÈÕ£¬£¬£¬£¬£¬£¬ÏÃÃÅ´óѧÏÄÄþÉÛ¡¢ÕÅÌìÓ¢¡¢Ô¬È¨ÍŶÓÏàÖú£¬£¬£¬£¬£¬£¬ÔÚ¡¶Signal Transduction and Targeted Therapy¡·ÆÚ¿¯½ÒÏþÁËÌâΪ¡°Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects¡±µÄÑо¿ÂÛÎÄ£¬£¬£¬£¬£¬£¬Ñо¿¿ª·¢ÁËÒ»ÖÖ²»Ò×ÓÕµ¼²¡¶¾ÖкͿ¹ÌåµÄÈÜÁö²¡¶¾¡ª¡ªrVSV-LCMVG£¬£¬£¬£¬£¬£¬²¢½øÒ»²½Ö¤ÊµÁ˸ÃÈÜÁö²¡¶¾Óë¹ý¼Ì×ªÒÆTϸ°û»òmRNA°©Ö¢ÒßÃçÁªºÏʹÓ㬣¬£¬£¬£¬£¬¿ÉÔöÇ¿¿¹Ö×ÁöЧ¹û¡£¡£¡£¡£¡£¡£
[1] Fu, R., Qi, R., Xiong, H. et al. Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects. Sig Transduct Target Ther 9, 118 (2024). https://doi.org/10.1038/s41392-024-01824-1